Augenheilkunde up2date 2017; 7(04): 315-328
DOI: 10.1055/s-0043-115321
Bindehaut, Hornhaut, Lederhaut
Georg Thieme Verlag KG Stuttgart · New York

Diagnostik und Therapie von Irisläsionen

Diagnosis and Therapy of Iris Lesions
Joel M. Mor
Konrad R. Koch
Ludwig M. Heindl
Further Information

Publication History

Publication Date:
20 November 2017 (online)


Teil des klinisch-ophthalmologischen Alltags ist die korrekte Diagnose tumoröser Irisläsionen. Insbesondere die Differenzialdiagnose und die Bewertung der Dignität anhand der Morphologie gestalten sich dabei oft schwierig. Dieser Beitrag gibt einen Überblick über das breite Spektrum von Iristumoren einschließlich empfohlener Diagnostik- und Therapiemodalitäten.


The most common iris lesions are iris nevi, iris melanomas and iris pigment epithelium cysts. However, there is an abundance of rare differential diagnoses that have to be considered, including other melanocytic and non-melanocytic lesions. Diagnostic tools include the slit lamp examination, gonioscopy, tonometry, transillumination, ultrasound biomicroscopy (UBM), optical coherence tomography, fluorescein angiography and standardized photography-assisted documentation. The timely identification of malignant lesions (i.e. iris melanoma) is paramount. To assess malignancy criteria of iris nevi, the ABCDEF rule (age young, blood, clock hour inferior, diffuse growth, ektropion uveae, feathery margins) can be applied. Statistically, up to 11% of iris nevi may develop into iris melanomas within 20 years. TNM Staging follows the 2010 AJCC cancer staging manual and helps determine the optimal treatment strategy. Treatment options include radiotherapy, such as plaque brachytherapy and proton beam radiation therapy, as well as surgical excision. Both the surgical and the radiotherapeutic approaches show comparable local tumor control rates. However, the spectrum of therapy-related side effects and complications may differ amongst treatment modalities. After initial treatment, patients should be followed up every 3 – 6 months. Tumor-related mortality ranges between 0 – 11% and is significantly lower than in other uveal melanomas. A prognostic value of common genetic alterations, which have been identified as significant prognostic factors in posterior uveal melanoma, could not be shown for iris melanoma.

  • Die häufigsten Iristumoren sind Irisnävi, Irismelanome und IPE-Zysten.

  • Eine Vielzahl seltener Differenzialdiagnosen muss erwogen werden. Dazu gehören z. B. stromale Iriszysten, Hämangiome und Metastasen anderer Tumoren.

  • Nicht neoplastische Läsionen können einen Tumor imitieren.

  • Die ABCDEF-Regel dient der Einschätzung des Entartungsrisikos von Irisnävi.

  • Die Therapie von Irismelanomen erfolgt mittels Resektion oder Bestrahlung.

  • Die Wahl der Therapiemodalität ist abhängig von einer Vielzahl an Faktoren und muss mit dem Patienten ausführlich diskutiert werden.

  • Die Prognose ist günstiger als beim Aderhaut- und Ziliarkörpermelanom.

  • Literatur

  • 1 Naumann GO, Rummelt V. Block excision of tumors of the anterior uvea. Report on 68 consecutive patients. Ophthalmology 1996; 103: 2017-2027 discussion 2027–2028
  • 2 Territo C, Shields CL, Shields JA. et al. Natural course of melanocytic tumors of the iris. Ophthalmology 1988; 95: 1251-1255
  • 3 Duke JR, Dunn SN. Primary tumors of the iris. Arch Ophthalmol 1958; 59: 204-214
  • 4 Ashton N. Primary tumours of the iris. Br J Ophthalmol 1964; 48: 650-668
  • 5 Heath P. Tumors of the iris. Classification and clinical followup. Trans Am Ophthalmol Soc 1964; 62: 51-82
  • 6 Shields CL, Kancherla S, Patel J. et al. Clinical survey of 3680 iris tumors based on patient age at presentation. Ophthalmology 2012; 119: 407-414
  • 7 Heindl LM, Bucher F, Naumann GO. et al. Lack of ciliary body lymphatics in iridociliary melanocytoma. Graefes Arch Clin Exp Ophthalmol 2014; 252: 169-171
  • 8 Heindl LM, Hofmann TN, Adler W. et al. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?. Ophthalmology 2010; 117: 334-342
  • 9 Shields CL, Shields PW, Manalac J. et al. Review of cystic and solid tumors of the iris. Oman J Ophthalmol 2013; 6: 159-164
  • 10 Heindl LM, Lotter M, Strnad V. et al. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study ] Ophthalmologe 2007; 104: 149-157
  • 11 Kivelä T. et al. Malignant Melanoma of the Uvea. In: Edge S, Byrd DR, Compton CC. et al. eds. AJCC Cancer Staging Manual. 7th ed. Berlin: Springer; 2010
  • 12 Naumann GO. Iris. In: Naumann GOH, Holbach LM, Kruse FE. eds. Applied Pathology for ophthalmic Microsurgeons. Berlin: Springer; 2008
  • 13 Shields CL, Furuta M, Thangappan A. et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol 2009; 127: 989-998
  • 14 Shields CL, Shields JA, Materin M. et al. Iris melanoma: risk factors for metastasis in 169 consecutive patients. Ophthalmology 2001; 108: 172-178
  • 15 Ristau T, Cursiefen C, Heindl LM. [Pseudo-tumor of the iris following cataract surgery]. Ophthalmologe 2013; 110: 770-772
  • 16 Nguyen NX, Küchle M, Strunk W. Tyndallometry for follow-up of iodine-125 brachytherapy of uveal malignant melanomas. Report of 2 patients. Klin Monatsbl Augenheilkd 1996; 209: 25-30
  • 17 Rummelt V, Naumann GOH. Uvea. In: Naumann GOH. Hrsg. Pathologie des Auges II. 2. Aufl.. Berlin: Springer; 1997
  • 18 Bianciotto C, Shields CL, Guzman JM. et al. Assessment of anterior segment tumors with ultrasound biomicroscopy versus anterior segment optical coherence tomography in 200 cases. Ophthalmology 2011; 118: 1297-1302
  • 19 Bechrakis NE, Foerster MH, Bornfeld N. Biopsy in indeterminate intraocular tumors. Ophthalmology 2002; 109: 235-242
  • 20 Lois N, Shields CL, Shields JA. et al. Primary cysts of the iris pigment epithelium: Clinical features and natural course in 234 patients. Ophthalmology 1998; 105: 1879-1885
  • 21 Lois N, Shields CL, Shields JA. et al. Primary iris stromal cysts: A report of 17 cases. Ophthalmology 1998; 105: 1317-1322
  • 22 Shields CL, Arepalli S, Lally EB. et al. Iris stromal cyst management with absolute alcohol-induced sclerosis in 16 patients. JAMA Ophthalmol 2014; 132: 703-708
  • 23 Shields CL, Kaliki S, Hutchinson A. et al. Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide. Ophthalmology 2013; 120: 766-772
  • 24 Koch KR, Ortmann M, Heindl LM. Extraocular Extension of a Benign Ciliary Body Nevus. JAMA Ophthalmol 2015; 133: e153137
  • 25 Heindl LM, Hofmann TN, Knorr HL. et al. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci 2009; 50: 1988-1995
  • 26 Shields CL, Kaliki S, Shah SU. et al. Iris melanoma features and prognosis in children and adults in 317 patients. The 2011 Leonard Apt Lecture. J AAPOS 2012; 16: 10-16
  • 27 Popovic M, Ahmed IIK, DiGiovanni J. et al. Radiotherapeutic and surgical management of iris melanoma: A review. Surv Ophthalmol 2017; 62: 302-311
  • 28 Willerding GD, Cordini D, Hackl C. Proton beam radiotherapy of diffuse iris melanoma in 54 patients. Br J Ophthalmol 2015; 99: 812-816
  • 29 Lumbroso-Le Rouic L, Charif Chefchaouni M, Levy C. et al. 125I plaque brachytherapy for anterior uveal melanomas. Eye (Lond) 2004; 18: 911-916
  • 30 Chaugule SS, Finger PT. Regression Patterns of Iris Melanoma after Palladium-103 (103Pd) Plaque Brachytherapy. Ophthalmology 2017; DOI: 10.1136/bjophthalmol-2017-310315.
  • 31 Damato B, Kacperek A, Chopra M. et al. Proton beam radiotherapy of iris melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 109-115
  • 32 Riechardt AI, Pilger D, Cordini D. et al. Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors. Graefes Arch Clin Exp Ophthalmol 2017; DOI: 10.1007/s00417-017-3737-3.
  • 33 Shields CL, Naseripour M, Shields JA. et al. Custom-designed plaque radiotherapy for nonresectable iris melanoma in 38 patients: tumor control and ocular complications. Am J Ophthalmol 2003; 135: 648-656
  • 34 American Brachytherapy Society – Ophthalmic Oncology Task Force, ABS – OOTF Committee. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy 2014; 13: 1-14
  • 35 Conway RM, Chua WCT, Qureshi C. et al. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol 2001; 85: 848e54
  • 36 Demirci H, Shields CL, Shields JA. et al. Diffuse iris melanoma: a report of 25 cases. Ophthalmology 2002; 109: 1553e60
  • 37 Heindl LM, Koch KR, Hermann MM. et al. Block excision of iridociliary tumors enables molecular profiling and immune vaccination. Ophthalmology 2017; 124: 268-270
  • 38 Koch KR, Heindl LM, Cursiefen C. et al. Artificial iris devices: benefits, limitations, and management of complications. J Cataract Refract Surg 2014; 40: 376-382
  • 39 Dogrusöz M, Jager MJ, Damato B. Uveal Melanoma Treatment and Prognostication. Asia Pac J Ophthalmol (Phila) 2017; 6: 186-196
  • 40 Shields CL, Ramasubramanian A, Ganguly A. et al. Cytogenetic testing of iris melanoma using fine needle aspiration biopsy in 17 patients. Retina 2011; 31: 574-580
  • 41 Harbour JW, Wilson D, Finger PT. et al. Gene expressing profiling of iris melanomas. Ophthalmology 2013; 120: 213 213.e1–3
  • 42 Shields JA, Bianciotto CG, Kligman B. et al. Vascular tumors of the iris. A review of 45 patients. The 2009 Helen Keller Lecture. Arch Ophthalmol 2010; 128: 1107-1112
  • 43 Shields JA, Shields CL. Tumors and related lesions of the pigmented epithelium. Asia Pac J Ophthalmol (Phila) 2017; 6: 215-223
  • 44 Chandran P, Rao HL, Mandal AK. et al. Glaucoma associated with iridocorneal endothelial syndrome in 203 Indian subjects. PLoS One 2017; 12: e0171884